---
document_datetime: 2025-12-02 05:24:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kivexa.html
document_name: kivexa.html
version: success
processing_time: 0.1110523
conversion_datetime: 2025-12-28 03:22:41.79302
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kivexa

[RSS](/en/individual-human-medicine.xml/66748)

##### Authorised

This medicine is authorised for use in the European Union

abacavir / lamivudine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kivexa](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kivexa is used with at least one other antiviral medicine to treat adults and children weighing at least 25 kg who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).

Kivexa contains two active substances, abacavir and lamivudine.

Expand section

Collapse section

## How is Kivexa used?

Kivexa can only be obtained with a prescription and should be prescribed by a doctor who has experience in managing HIV infection. It is available as tablets, each containing abacavir 600 mg and lamivudine 300 mg.

Before starting treatment with abacavir, all patients should have a test to find out if they have a gene called 'HLA?B (type 5701)'. Patients with this gene are at an increased risk of having an allergic reaction to abacavir, so they should not take Kivexa.

The dose of Kivexa is one tablet once a day. Patients who need to adjust the dose of abacavir or lamivudine should take the medicines separately.

For more information about using Kivexa, see the package leaflet or contact your doctor or pharmacist.

## How does Kivexa work?

Both active substances in Kivexa, abacavir and lamivudine, are nucleoside reverse transcriptase inhibitors (NRTIs). They work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to make more copies of itself in the cells it has infected and so spread in the body. Kivexa, taken with at least one other HIV medicine, reduces the amount of HIV in the blood and keeps it at a low level. Kivexa does not cure HIV infection, but it holds off damage to the immune system and the development of infections and diseases associated with AIDS.

Both active substances have been available in the European Union (EU) since the late 1990s: abacavir has been authorised as Ziagen since 1999, and lamivudine has been authorised as Epivir since 1996.

## What benefits of  Kivexa have been shown in studies?

Kivexa was shown to be effective against HIV in three main studies involving a total of 1,230 patients. At the time of Kivexa's authorisation, abacavir was authorised at a dose of 300 mg twice a day. Therefore, the studies compared abacavir taken at a dose of 600 mg once a day and at a dose of 300 mg twice a day, in combination with lamivudine and one or two other antiviral medicines. The main measure of effectiveness was the change in the level of HIV in the blood (viral load) after 24 or 48 weeks of treatment.

Two studies used the active substances, abacavir and lamivudine, taken as separate medicines. Both doses of abacavir, taken in combination with lamivudine and other antiviral medicines, were equally effective in reducing viral loads. In the first study, 66% (253 out of 384) of the patients taking abacavir once a day had undetectable viral loads (below 50 copies/ml) after 48 weeks of treatment, compared with 68% (261 out of 386) of the patients taking it twice a day.

The third study used a combination tablet for the once-daily dose. The combination tablet taken once a day was as effective as the medicines taken separately twice a day in reducing viral loads over 24 weeks of treatment.

## What are the risks associated with Kivexa?

The most common side effects with Kivexa (which may affect up to 1 in 10 people) are hypersensitivity (allergic reactions), rash, nausea (feeling sick), vomiting, diarrhoea, abdominal (belly) pain, headache, joint pain, muscle disorders, cough, nasal symptoms (nose problems, such as irritation and runny nose), fever, lethargy (lack of energy), tiredness, insomnia (difficulty sleeping), feeling unwell, loss of appetite and hair loss. For the full list of side effects of Kivexa, see the package leaflet.

Hypersensitivity reactions occur in patients taking Kivexa, usually within the first 6 weeks of treatment, and can be life-threatening. The risk of hypersensitivity is higher in patients who have the HLA?B (type 5701) gene. Symptoms almost always include fever or rash, but also very commonly include nausea, vomiting, diarrhoea, abdominal pain, dyspnoea (difficulty breathing), cough, lethargy, feeling unwell, headache, blood tests showing signs of liver damage and muscle pain. Treatment with Kivexa should be stopped promptly if the patient has a hypersensitivity reaction. For more information and the full list of restrictions, see the package leaflet.

## Why is Kivexa authorised in the EU?

The European Medicines Agency decided that Kivexa's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Kivexa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kivexa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Kivexa are continuously monitored. Side effects reported with Kivexa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kivexa

Kivexa received a marketing authorisation valid throughout the EU on 17 December 2004.

Kivexa : EPAR - Medicine overview

Reference Number: EMA/194712/2020

English (EN) (129.24 KB - PDF)

**First published:** 14/01/2008

**Last updated:** 23/07/2020

[View](/en/documents/overview/kivexa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-350)

български (BG) (154.54 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/bg/documents/overview/kivexa-epar-medicine-overview_bg.pdf)

español (ES) (129.53 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/es/documents/overview/kivexa-epar-medicine-overview_es.pdf)

čeština (CS) (153.1 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/cs/documents/overview/kivexa-epar-medicine-overview_cs.pdf)

dansk (DA) (127.97 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/da/documents/overview/kivexa-epar-medicine-overview_da.pdf)

Deutsch (DE) (131.62 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/de/documents/overview/kivexa-epar-medicine-overview_de.pdf)

eesti keel (ET) (115.65 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/et/documents/overview/kivexa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (155.2 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/el/documents/overview/kivexa-epar-medicine-overview_el.pdf)

français (FR) (131.01 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/fr/documents/overview/kivexa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (151.64 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/hr/documents/overview/kivexa-epar-medicine-overview_hr.pdf)

italiano (IT) (128.27 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/it/documents/overview/kivexa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (169.18 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/lv/documents/overview/kivexa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (152.81 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/lt/documents/overview/kivexa-epar-medicine-overview_lt.pdf)

magyar (HU) (150.86 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/hu/documents/overview/kivexa-epar-medicine-overview_hu.pdf)

Malti (MT) (155.1 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/mt/documents/overview/kivexa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (128.75 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/nl/documents/overview/kivexa-epar-medicine-overview_nl.pdf)

polski (PL) (156.25 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/pl/documents/overview/kivexa-epar-medicine-overview_pl.pdf)

português (PT) (130.39 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/pt/documents/overview/kivexa-epar-medicine-overview_pt.pdf)

română (RO) (150.8 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/ro/documents/overview/kivexa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (153.27 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/sk/documents/overview/kivexa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (150.43 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/sl/documents/overview/kivexa-epar-medicine-overview_sl.pdf)

Suomi (FI) (126.86 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/fi/documents/overview/kivexa-epar-medicine-overview_fi.pdf)

svenska (SV) (128.08 KB - PDF)

**First published:**

14/01/2008

**Last updated:**

23/07/2020

[View](/sv/documents/overview/kivexa-epar-medicine-overview_sv.pdf)

## Product information

Kivexa : EPAR - Product Information

English (EN) (627.4 KB - PDF)

**First published:** 16/07/2007

**Last updated:** 27/11/2023

[View](/en/documents/product-information/kivexa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-220)

български (BG) (787.22 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/bg/documents/product-information/kivexa-epar-product-information_bg.pdf)

español (ES) (615.85 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/es/documents/product-information/kivexa-epar-product-information_es.pdf)

čeština (CS) (733.54 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/cs/documents/product-information/kivexa-epar-product-information_cs.pdf)

dansk (DA) (668 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/da/documents/product-information/kivexa-epar-product-information_da.pdf)

Deutsch (DE) (409.18 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/de/documents/product-information/kivexa-epar-product-information_de.pdf)

eesti keel (ET) (650.92 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/et/documents/product-information/kivexa-epar-product-information_et.pdf)

ελληνικά (EL) (584.43 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/el/documents/product-information/kivexa-epar-product-information_el.pdf)

français (FR) (707.92 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/fr/documents/product-information/kivexa-epar-product-information_fr.pdf)

hrvatski (HR) (759.9 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/hr/documents/product-information/kivexa-epar-product-information_hr.pdf)

íslenska (IS) (624.35 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/is/documents/product-information/kivexa-epar-product-information_is.pdf)

italiano (IT) (634.69 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/it/documents/product-information/kivexa-epar-product-information_it.pdf)

latviešu valoda (LV) (703.49 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/lv/documents/product-information/kivexa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (693.51 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/lt/documents/product-information/kivexa-epar-product-information_lt.pdf)

magyar (HU) (735.69 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/hu/documents/product-information/kivexa-epar-product-information_hu.pdf)

Malti (MT) (872.6 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/mt/documents/product-information/kivexa-epar-product-information_mt.pdf)

Nederlands (NL) (624.34 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/nl/documents/product-information/kivexa-epar-product-information_nl.pdf)

norsk (NO) (620.9 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/no/documents/product-information/kivexa-epar-product-information_no.pdf)

polski (PL) (701.63 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/pl/documents/product-information/kivexa-epar-product-information_pl.pdf)

português (PT) (604.46 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/pt/documents/product-information/kivexa-epar-product-information_pt.pdf)

română (RO) (714.86 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/ro/documents/product-information/kivexa-epar-product-information_ro.pdf)

slovenčina (SK) (668.14 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/sk/documents/product-information/kivexa-epar-product-information_sk.pdf)

slovenščina (SL) (665.73 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/sl/documents/product-information/kivexa-epar-product-information_sl.pdf)

Suomi (FI) (641.32 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/fi/documents/product-information/kivexa-epar-product-information_fi.pdf)

svenska (SV) (611.76 KB - PDF)

**First published:**

16/07/2007

**Last updated:**

27/11/2023

[View](/sv/documents/product-information/kivexa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00000011/202212 15/11/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kivexa : EPAR - All Authorised presentations

English (EN) (48.49 KB - PDF)

**First published:** 26/02/2008

**Last updated:** 12/11/2015

[View](/en/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-946)

български (BG) (36.59 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/bg/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_bg.pdf)

español (ES) (48.84 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/es/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (77.27 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/cs/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (14.01 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/da/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14.74 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/de/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (75.64 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/et/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (427.78 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/el/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_el.pdf)

français (FR) (17.43 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/fr/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (20.37 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/hr/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (52.22 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/is/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (22.47 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/it/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (34.23 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/lv/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (78.78 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/lt/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (41.51 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/hu/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (39.33 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/mt/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.58 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/nl/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (12.09 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/no/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.62 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/pl/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.49 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/pt/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_pt.pdf)

română (RO) (36.59 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/ro/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.44 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/sk/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (32.05 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/sl/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (29.65 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/fi/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.21 KB - PDF)

**First published:**

26/02/2008

**Last updated:**

12/11/2015

[View](/sv/documents/all-authorised-presentations/kivexa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kivexa Active substance

- abacavir
- lamivudine

International non-proprietary name (INN) or common name

- abacavir
- lamivudine

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR02

### Pharmacotherapeutic group

- Antivirals for treatment of HIV infections, combinations
- Antivirals for systemic use

### Therapeutic indication

Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.

Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

## Authorisation details

EMA product number EMEA/H/C/000581 Marketing authorisation holder

ViiV Healthcare BV

Van Asch van Wijckstraat 55H

Marketing authorisation issued 16/12/2004 Revision 37

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kivexa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (414.23 KB - PDF)

**First published:** 16/07/2009

**Last updated:** 23/08/2022

[View](/en/documents/procedural-steps-after/kivexa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Kivexa-H-C-PSUSA-00000011-202212 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (103.03 KB - PDF)

**First published:** 27/11/2023

[View](/en/documents/scientific-conclusion/kivexa-h-c-psusa-00000011-202212-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Kivexa : EPAR - Procedural steps taken before authorisation

English (EN) (461.31 KB - PDF)

**First published:** 07/08/2006

**Last updated:** 27/11/2023

[View](/en/documents/procedural-steps/kivexa-epar-procedural-steps-taken-authorisation_en.pdf)

Kivexa : EPAR - Scientific Discussion

English (EN) (336.27 KB - PDF)

**First published:** 07/08/2006

**Last updated:** 07/08/2006

[View](/en/documents/scientific-discussion/kivexa-epar-scientific-discussion_en.pdf)

#### News on Kivexa

[Updated advice on body fat changes and lactic acidosis with HIV medicines](/en/news/updated-advice-body-fat-changes-lactic-acidosis-hiv-medicines) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/11/2023

## Share this page

[Back to top](#main-content)